Chimeric Therapeutics Limited (CHMMF)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in AUDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | 0 | 0 | 3 | 5 | 0 | 4 | - | - |
| Operating profit | AUD m | -15 | - | ||||||
| Net profit | AUD m | -0 | -15 | -16 | -26 | -13 | -10 | - | - |
| EPS reported | AUD | -0.77 | - | ||||||
| Operating cashflow per share | AUD | -0.54 | - | ||||||
| Capex per share | AUD | 0.00 | - | ||||||
| FCF per share | AUD | -0.54 | - | ||||||
| Free cash flow | AUD m | -7 | - | ||||||
| Net debt | AUD m | -6 | - | ||||||
| Book value equity | AUD m | 2 | - | ||||||
| Book value per share | AUD | 0.15 | - | ||||||
| Number of shares | m | 13.52 | - | ||||||
| DPS (TTM paid) | AUD | 0.00 | - |
Financial summary
Financials in AUDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.04 | - | ||||||
| P/S LTM | x | 0.52 | - | ||||||
| P/FCF LTM | x | -0.28 | - | ||||||
| EV/EBITDA LTM | x | 0.41 | - | ||||||
| EV/Sales LTM | x | -0.93 | - | ||||||
| Earnings Yield LTM | % | -5.08% | - | ||||||
| FCF Yield | % | -354.20% | - | ||||||
| Quality | |||||||||
| ROE | % | -528.25% | - | ||||||
| ROIC | % | -2.17% | - | ||||||
| Operating margin | % | -3.81% | - | ||||||
| Gross margin | % | +78.66% | - | ||||||
| FCF/Sales | % | -183.34% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.63 | - | ||||||
| EBIT/Net interest | x | -71.61 | - | ||||||
| Net debt/market cap | % | 0.00% | - | ||||||
| Net debt/Equity | x | -2.92 | - | ||||||
| Gross debt/equity | x | 0.00 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Chimeric Therapeutics Limited is an Australian biotechnology firm operating at the clinical stage, dedicated to advancing and commercializing a diverse portfolio of cell-based treatments specifically for cancer. Its pipeline features several promising candidates. CHM 0201, utilizing a core natural killer (NK) cell platform, is currently undergoing Phase I clinical trials for the treatment of both solid tumors and hematological malignancies. Another key program, CHM 1101 (a CLTX CAR T-cell therapy), is also in Phase I development, specifically targeting patients with recurrent or progressive glioblastoma that expresses MMP2. Beyond these lead programs, the company is actively developing a range of other innovative therapies. These include CHM 0301 for various blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK), both designed to combat solid tumors. The CLTX CAR T-cell therapy, CHM 1101, is additionally being explored for indications such as melanoma, colorectal, and prostate cancers. Furthermore, CHM 2101 (CDH17 CAR T) is under development for neuroendocrine, colorectal, pancreatic, and gastric cancers. Established in 2020, Chimeric Therapeutics Limited maintains its headquarters in Carlton, Australia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Chimeric Therapeutics Limited is an Australian biotechnology firm operating at the clinical stage, dedicated to advancing and commercializing a diverse portfolio of cell-based treatments specifically for cancer. Its pipeline features several promising candidates. CHM 0201, utilizing a core natural killer (NK) cell platform, is currently undergoing Phase I clinical trials for the treatment of both solid tumors and hematological malignancies. Another key program, CHM 1101 (a CLTX CAR T-cell therapy), is also in Phase I development, specifically targeting patients with recurrent or progressive glioblastoma that expresses MMP2. Beyond these lead programs, the company is actively developing a range of other innovative therapies. These include CHM 0301 for various blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK), both designed to combat solid tumors. The CLTX CAR T-cell therapy, CHM 1101, is additionally being explored for indications such as melanoma, colorectal, and prostate cancers. Furthermore, CHM 2101 (CDH17 CAR T) is under development for neuroendocrine, colorectal, pancreatic, and gastric cancers. Established in 2020, Chimeric Therapeutics Limited maintains its headquarters in Carlton, Australia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free